secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALBIREO PHARMA, INC. (—)
CIK:        0001322505
Form:       8-K
Filed at:   2023-03-02T23:59:59+00:00
Accession:  0001104659-23-027946
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Albireo Pharma acquired by Ipsen for $42/share plus CVR; tender offer completed, merger effective March 2, 2023
--------------------------------------------------------------------------------

- Tender offer expired March 1, 2023; 12,229,316 shares (59%) validly tendered, plus 5,618,538 (27%) by guaranteed delivery.
- Aggregate closing amount approximately $880 million; each share converted to $42.00 cash plus one CVR worth up to $10.00.
- Merger completed under DGCL Section 251(h); Albireo now wholly owned subsidiary of Ipsen Biopharmaceuticals.
- Nasdaq trading suspended as of March 2, 2023; company to file Form 15 to deregister shares and suspend SEC reporting.
- Board and officers replaced: Francois Garnier and Aymeric Le Chatelier become directors; Christelle Huguet and Jennifer Benenson become officers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1322505/000110465923027946/0001104659-23-027946-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1322505/000110465923027946/tm238312d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-027946

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer